August 5, 2020         
Welltower Reports Second Quarter 2020 Results   •   Launch Sequence Initiated: Pikmin 3 Deluxe Lands on Nintendo Switch on Oct. 30   •   Consumers Are More Likely to Post Online Reviews for Larger Ticket Home Improvement Items, J.D. Power Finds   •   Preliminary Injunction Hearing Scheduled Concerning Religious And Private School Classroom Shutdown   •   Bayer and Direct Relief Team Up to Help Remove Barriers So More Women Can Gain Access to Contraceptives   •   AARP Survey: 83% of Global Executives Agree Multigenerational Workforce is Key to Growth and Success   •   Children's puppet act wins Zigazoo "media star competition"   •   Kane Brown and The Crown Royal Purple Bag Project Team Up with Veterans to Release "Homesick (Veterans Version)" and Give Back t   •   The Royal Canadian Mint Recognizes the 150th Anniversary of the Northwest Territories in its Newest Suite of Collector Coins   •   Publix Recalls Red Onions Due to Possible Salmonella Risk   •   Tired of Meal Replacement Shakes That Taste Like Flavored Dirt, First-Time Entrepreneurs Launch Soul ShāXe in the Midst of   •   Statement on Donation of over 60,000 N95 Masks to Community Centers Providing Health and Mental Health Services to Underserved H   •   GOJO is Supporting K-12 Schools with PURELL® Products, Education, and Training   •   Capri Holdings Limited Announces First Quarter Fiscal 2021 Results   •   INTERNATIONAL YOUTH DAY: DKT International Highlights Teens and Youth Ambassadors Educating Peers About Sex and Family Planning   •   The Committee of 100 Donates 850,000 N95 Masks to Communities in Need   •   e.l.f. Beauty and Alicia Keys Announce the Creation of A Lifestyle Beauty Brand   •   Women’s Public Leadership Network Awards Half-Million Dollars to Break Barriers for Female Candidates   •   Leading Senior Groups Announce Opposition to Proposition 21   •   Senior Care Authority Franchisee Earns Rockstar Recognition From Franchise Business Review
Bookmark and Share

Two New Publications Support the Safety and Efficacy of Slynd™ (drospirenone) tablets, 4 mg

Two New Publications Support the Safety and Efficacy of Slynd™ (drospirenone) tablets, 4 mg

PR Newswire

FLORHAM PARK, N.J., July 7, 2020 /PRNewswire/ -- Exeltis USA, Inc., a division of Insud Pharma, today communicated that 2 new articles published in Contraception and The European Journal of Contraception & Reproductive Health Care, reviewed the US Phase III clinical study involving Slynd (drospirenone) tablets 4 mg, a novel estrogen-free oral contraceptive in a physician and patient communication letter.

The publications highlighted the safety and efficacy of drospirenone 4 mg, similarly to the FDA which approved the Slynd NDA in May 2019. The first in Contraception, "A one-year prospective, open-label, single arm, multicenter phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only drospirenone 4 mg using a 24/4 daily regimen" (Kimble et al; February 21, 2020), indicated that drospirenone provides a contraceptive option for the majority of women regardless of blood pressure and BMI. The second, "Estrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and review of the literature" (Palacios et al; April 21, 2020), published in The European Journal of Contraception & Reproductive Healthcare-, concluded that drospirenone 4mg has shown contraceptive effectiveness similar to that of currently available COCs (combined oral contraceptives), very low cardiovascular side effects and a favorable bleeding pattern.

"We are pleased to see the Slynd clinical study results being reported in renowned journals," said  Randi Rievman, Senior Director, Marketing and Sales Training for Exeltis. "The data validates what we have known for some time: Slynd is an attractive option for many women who want or need an estrogen-free oral contraceptive. It offers  the right balance of safety and efficacy to address the needs of many women, especially for those who may not be good candidates for other currently available oral contraceptive options."

In addition to these findings, Exeltis USA President Salustiano Perez added, "Slynd is further differentiated in the market because it is an estrogen-free oral contraceptive product that provides a 24 active plus 4 inactive tablet dosing regimen and allows a 24-hour missed pill window."

Slynd is indicated to prevent pregnancy among females of reproductive potential. Slynd is contraindicated in females with conditions that predispose to hyperkalemia (e.g. renal impairment, hepatic impairment, and adrenal insufficiency). Other contraindications include presence or history of progestin sensitive cancers, liver tumors, benign or malignant, or undiagnosed abnormal uterine bleeding. Slynd may cause side effects including hyperkalemia, thromboembolism, bone loss, cervical cancer, liver problems, ectopic pregnancy, high blood sugar, changes in menstrual bleeding or depression. Discontinue Slynd if a thromboembolic event occurs or there are acute or chronic changes in liver function. For full important risk and use information about Slynd please see full Slynd Prescribing Information.

About Exeltis:

Exeltis is a fast-growing division of Madrid-based Insud Pharma, an integrated health sciences group. It has developed a leading position in the women's health sector, where it continues to discover, develop, produce and seek new medicines and medical devices to improve the health and wellbeing of women around the world. With a geographical footprint spanning over 40 countries, Exeltis employs over 4,000 professionals supported by a global production network. Exeltis strives to provide care for women throughout their lives. Exeltis offers a broad portfolio of products to respond to patients' needs in Women's Health including contraception, pregnancy, birth, and menopause and has expanded its reach in recent years to Central Nervous System (CNS), ophthalmology and endocrinology. In addition, to learn more, please visit us at exeltisusa.com.

For more information on Slynd™ and Important Risk Information, please visit slynd.com

Slynd is a trademark of Exeltis USA, Inc.

Cision View original content:http://www.prnewswire.com/news-releases/two-new-publications-support-the-safety-and-efficacy-of-slynd-drospirenone-tablets-4-mg-301088590.html

SOURCE Exeltis USA



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News